Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Selenium-binding protein 1 (SELENBP1) is a highly conserved intracellular protein that covalently binds selenium and belongs to the selenium-binding protein family. It exhibits methanethiol oxidase activity, converting methanethiol—a gut bacteria-derived organosulfur compound—into products such as hydrogen peroxide and hydrogen sulfide, which participate in redox regulation and cell signaling. SELENBP1 is implicated in critical biological functions including redox balance, intracellular protein degradation, intra-Golgi protein transport, and cell differentiation and motility. It has gained attention for its tumor suppressor role, as downregulation in various cancers is associated with poor outcomes. Additionally, altered SELENBP1 levels serve as biomarkers for cancer prognosis, cardiac injury, and neurological trauma. Its exact physiological and pathological roles remain an active area of research, and there are no approved drugs directly targeting SELENBP1 as of 2024.
Not applicable (no direct pharmacological inhibitors or activators established for SELENBP1 as of 2024)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Selenium-binding protein 1 (SELENBP1).